TNG462 has a PRMT5·MTA Ki ≤ 300 fM, HAP1 MTAP-null cellular SDMA IC50 =800 pM and viability GI50 = 4 nM, an average 45-fold selectivityagainst MTAP WT cells, displays consistent pharmacokinetic propertiesacross preclinical species with a predicted T1/2 in humans >24 h, and is in Phase 1/2 clinical trialsfor MTAP-deleted cancers (NCT05732831). This evidence concerns the gene PRMT5 and cancer.